Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Glass

Showing results (101-110 of 125) with videos related to

Pageof 13
Sort By:
British Journal of Pharmacology|April 1, 2011
A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injuryBėla Horváth, Lital Magid, Partha Mukhopadhyay, et al.
Journal of Medicinal Chemistry|December 20, 2021
Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking BehaviorThuy Nguyen, Thomas F Gamage, David B Finlay, et al.
Pharmacology Research & Perspectives|January 18, 2022
Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018David B Finlay, Thuy Nguyen, Thomas F Gamage, et al.
ACS Chemical Neuroscience|July 16, 2016
Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their AnaloguesSamuel D Banister, Mitchell Longworth, Richard Kevin, et al.
Lipids|November 9, 2021
Neuroprotective activity of new Δ3-N-acylethanolamines in a focal ischemia stroke modelRahau S Shirazi, Mikhail Vyssotski, Kirill Lagutin, et al.
Drug Testing and Analysis|October 10, 2019
Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines, and cannabinoids in human whole blood by liquid chromatography-tandem mass spectrometry - A New Zealand perspective of use in 2018Rui Shen Ong, Diana C Kappatos, Sarah G G Russell, et al.
Neurobiology of Disease|September 26, 2020
Inconsistencies in histone acetylation patterns among different HD model systems and HD post-mortem brainsPritika Narayan, Suzanne Reid, Emma L Scotter, et al.
ACS Chemical Neuroscience|October 15, 2020
Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICAAdam Ametovski, Christa Macdonald, Jamie J Manning, et al.
ACS Chemical Neuroscience|April 5, 2013
The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuseSamuel D Banister, Shane M Wilkinson, Mitchell Longworth, et al.
ACS Chemical Neuroscience|April 30, 2015
Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135Samuel D Banister, Jordyn Stuart, Richard C Kevin, et al.
Pageof 13

Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
British Journal of Pharmacology|April 1, 2011
A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injuryBėla Horváth, Lital Magid, Partha Mukhopadhyay, et al.
Journal of Medicinal Chemistry|December 20, 2021
Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking BehaviorThuy Nguyen, Thomas F Gamage, David B Finlay, et al.
Pharmacology Research & Perspectives|January 18, 2022
Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018David B Finlay, Thuy Nguyen, Thomas F Gamage, et al.
ACS Chemical Neuroscience|July 16, 2016
Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their AnaloguesSamuel D Banister, Mitchell Longworth, Richard Kevin, et al.
Lipids|November 9, 2021
Neuroprotective activity of new Δ3-N-acylethanolamines in a focal ischemia stroke modelRahau S Shirazi, Mikhail Vyssotski, Kirill Lagutin, et al.
Drug Testing and Analysis|October 10, 2019
Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines, and cannabinoids in human whole blood by liquid chromatography-tandem mass spectrometry - A New Zealand perspective of use in 2018Rui Shen Ong, Diana C Kappatos, Sarah G G Russell, et al.
Neurobiology of Disease|September 26, 2020
Inconsistencies in histone acetylation patterns among different HD model systems and HD post-mortem brainsPritika Narayan, Suzanne Reid, Emma L Scotter, et al.
ACS Chemical Neuroscience|October 15, 2020
Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICAAdam Ametovski, Christa Macdonald, Jamie J Manning, et al.
ACS Chemical Neuroscience|April 5, 2013
The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuseSamuel D Banister, Shane M Wilkinson, Mitchell Longworth, et al.
ACS Chemical Neuroscience|April 30, 2015
Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135Samuel D Banister, Jordyn Stuart, Richard C Kevin, et al.
Pageof 13